**8. Conclusion**

HE4, a secretory glycoprotein is over-expressed in ovarian cancer most commonly in the serous and endometriod variants. It is a complementary biomarker to CA125. When HE is used in combination with CA125, the diagnostic and prognostic performance of ovarian cancer is increased significantly. HE4 is involved in oncogenesis by promoting cellular growth, proliferation, metastasis and chemoresistance in ovarian cancer. HIF1a and Interleukin 8 are associated pro-angiogenetic factors, which are up-regulated by STAT3 pathway. Angiogenetic action of HE4 is also associated with epidermal growth factor, vascular endothelial growth factor (VEGF) and insulin which promoted nuclear translocations. So, research on HE4 may decode some novel mechanisms of oncogenesis to provide alternative therapeutic options.
